Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 6/20 | 0.83 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24183463 | 1.00 | ADRA2C (0.83) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL24183535 | 0.93 | ADRA2C (0.78) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL29787285 | 0.93 | ADRA2C (0.78) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL29787322 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL24183555 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL30398366 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL25426308 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL25426753 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL29787244 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B | |
| SCHEMBL30359158 | 0.93 | ADRA2C (0.84) | ADRA2CHRH3MAPK8ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136863-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120025327-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025328-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-114929694-B | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4175954-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2023-05-10 | — | — | EP | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-114929694-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-4021905-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | Bayer Aktiengesellschaft (DE) | 2022-07-06 | — | — | EP | disclosed |